Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Deere, Baxter, EPAM Systems, NiSource and Universal Display

Read MoreHide Full Article

For Immediate Release

Chicago, IL – August 16, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Deere (DE - Free Report) , Baxter (BAX - Free Report) , EPAM Systems (EPAM - Free Report) , NiSource (NI - Free Report) and Universal Display (OLED - Free Report) .

Here are highlights from Thursday’s Analyst Blog:

Top Analyst Reports: Deere, Baxter and More

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 11 major stocks, including Deere and Baxter. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Deere’s shares have gained +6.1% in the past year, underperforming the Zacks Farm Equipment industry, which has increased +7.6% over the same period. For fiscal 2019, Deere expects net sales to increase 5% year over year and net income at $3.3 billion. Concerns stemming from the U.S-China trade war and lower commodity prices have led to farmers getting cautious about their equipment purchases.

However, the Zacks analyst thinks the $16 billion aid program for American farmers impacted by the trade war is likely to bolster agricultural equipment sales, which bodes well for Deere. Improving construction markets and the Wirtgen acquisition which has increased Deere's exposure to global transportation infrastructure will benefit results.

Additionally, introduction of advanced technologies in its products will aid growth. However, raw material cost inflation, elevated expenses and unfavorable foreign currency impact remain concerns. 

Baxter’s shares have gained +21.7% in the past year, outperforming the Zacks Medical Products industry's increase of +7.6%. The Zacks analyst thinks Baxter continues to benefit from its core Advanced Surgery and Acute Therapies units.

Baxter’s surgical portfolio is expected to generate huge profits on the back of products like FLOSEAL Hemostatic Matrix, TISSEEL Fibrin Sealant among others. During the second quarter, the company received approval for the first and only ready-to-use insulin for IV infusion in hospitals and other acute care facilities.

With respect to quarterly results, Baxter ended the second quarter of 2019 on a solid note, beating expectations on both counts. However, Baxter’s Clinical Nutrition unit has witnessed sluggishness in recent times. Cutthroat competition in the MedTech markets is indicative of dull prospects.

Other noteworthy reports we are featuring today include EPAM Systems, NiSource and Universal Display.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just releasedCentury of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                   

http://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.